Research programme: osteoarthritis therapy - Genentech

Drug Profile

Research programme: osteoarthritis therapy - Genentech

Latest Information Update: 02 Nov 2005

Price : $50

At a glance

  • Originator Genentech
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Osteoarthritis

Most Recent Events

  • 02 Nov 2005 No development reported - Preclinical for Osteoarthritis in USA (unspecified route)
  • 21 May 2001 New profile
  • 21 May 2001 Preclinical development for Osteoarthritis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top